Memorial Hospital Research Laboratories
The Elli Papaemmanuil Lab
Our lab is a collective of clinical, computational, molecular and mathematic research investigators with an interest in studying the role of acquired mutations in cancer development, and how these determine clinical phenotype and response to therapy. Our mission is to execute research that informs and moves clinical practices in oncology forward. We have strong expertise in genome profiling analysis, a proven track record on the development of high-throughput laboratory and analytical pipelines (bioinformatics and statistical), and integrating large and complex genomic datasets. We have formed a strong network of research and clinical collaborations to pursue innovative studies in cancer research.
We like to perform ambitious research, but operate in a fun, collaborative, and team-oriented environment, and we are strongly committed to mentoring young scientists through internal and international internship schemes.
Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, Alexandrov LB, Van Loo P, Cooke SL, Marshall J, Martincorena I, Hinton J, Gundem G, van Delft FW, Nik-Zainal S, Jones DR, Ramakrishna M, Titley I, Stebbings L, Leroy C, Menzies A, Gamble J, Robinson B, Mudie L, Raine K, O’Meara S, Teague JW, Butler AP, Cazzaniga G, Biondi A, Zuna J, Kempski H, Muschen M, Ford AM, Stratton MR, Greaves M, Campbell PJ. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014 Feb;46(2):116-25. doi: 10.1038/ng.2874. Epub 2014 Jan 12. PubMed Central PMCID: PMC3960636. PubMed
Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jädersten M, Dolatshad H, Verma A, Cross NC, Vyas P, Killick S, Hellström-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun. 2015 Jan 9;6:5901. doi: 10.1038/ncomms6901. PubMed Central PMCID: PMC4338540. PubMed
Gerstung M, Papaemmanuil E, Campbell PJ. Subclonal variant calling with multiple samples and prior knowledge. Bioinformatics. 2014 May 1;30(9):1198-204. doi: 10.1093/bioinformatics/btt750. Epub 2014 Jan 16. PubMed Central PMCID: PMC3998123. PubMed
Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A, Shlien A, Groves MJ, Forbes SA, Raine K, Hinton J, Mudie LJ, McLaren S, Hardy C, Latimer C, Della Porta MG, O’Meara S, Ambaglio I, Galli A, Butler AP, Walldin G, Teague JW, Quek L, Sternberg A, Gambacorti-Passerini C, Cross NC, Green AR, Boultwood J, Vyas P, Hellstrom-Lindberg E, Bowen D, Cazzola M, Stratton MR, Campbell PJ; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013 Nov 21;122(22):3616-27; quiz 3699. doi: 10.1182/blood-2013-08-518886. Epub 2013 Sep 12. PubMed Central PMCID: PMC3837510. PubMed
Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Tomlinson IP, Taylor M, Greaves M, Houlston RS. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet. 2009 Sep;41(9):1006-10. doi: 10.1038/ng.430. Epub 2009 Aug 16. PubMed
Elli Papaemmanuil, PhD
- Molecular geneticist Elli Papaemmanuil performs systematic interrogations of well-annotated clinical trial cohorts in leukemia and cancer to explore how the compound genetic and clonal architecture in patients' leukemias and tumors dictate clinical phenotype, disease progression, and clinical outcomes.
- PhD – University of London, London, England, UK
- Memorial Hospital Research Laboratories
- Epidemiology & Biostatistics
- Cancer Biology & Genetics Program
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology
- Center for Hematologic Malignancies
- Geoffrey Beene Cancer Research Center
- Gerstner Sloan Kettering Graduate School of Biomedical Sciences
- Josie Robertson Investigator (2015-2020)
- European Hematology Association Young Investigator Award
- Cancer Research UK Career Development Award
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Elli Papaemmanuil discloses the following relationships and financial interests:
Kyowa Hakko Kirin Pharma
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.